Medication-assisted treatment training for OUD reduces bias and stigma, improves care

After a decade of expeditions around the world, Kentucky-based emergency medicine physician Ben Mattingly, MD, has finally summited the highest mountain on each continent —

Gilead dis­con­tin­ued its re­main­ing Phase III study of ma­grolimab, an an­ti-CD47 an­ti­body that the com­pa­ny was test­ing for acute myeloid leukemia and its pre­cur­sor dis­ease,